AnaptysBio, Inc. manages royalty-focused financial collaborations tied to Jemperli with GSK and imsidolimab with Vanda. Following the completed separation of First Tracks Biotherapeutics, the company’s recurring updates center on royalty asset management, collaboration economics, contractual rights, stock repurchase activity, and governance changes.
News about ANAB also includes developments involving imsidolimab, a licensed antibody asset being developed by Vanda, and legal or contractual matters related to the Jemperli collaboration. Company announcements have additionally covered board and finance leadership appointments and the corporate transition from a biopharma operations business to a streamlined royalty management model.
Anaptys (Nasdaq: ANAB) appointed Christopher M. Murphy as chief financial officer and Owen Hughes to its board of directors, effective May 11, 2026.
Murphy brings investment banking, corporate strategy and biotech CFO experience, while Hughes adds deep royalty management, corporate development and investment management expertise.
Anaptys (Nasdaq: ANAB) announced that Daniel Faga, president and CEO, will participate in a fireside chat at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference on Wednesday, May 6, 2026 at 1:30pm ET. Registration is available via the conference website.
Vanda Pharmaceuticals (ANAB) announced publication of a peer‑reviewed NEJM Evidence article reporting the pivotal phase III study of imsidolimab for Generalized Pustular Psoriasis (GPP).
The study findings are included in a Biologics License Application (BLA) for imsidolimab submitted to the U.S. FDA, with a target action date of December 12, 2026.
Summary not available.
Anaptys (Nasdaq: ANAB) completed the taxable spin-off of First Tracks Biotherapeutics (trading as TRAX) on April 20, 2026, distributing one First Tracks share per Anaptys share held as of the April 6, 2026 record date. Anaptys now exclusively manages royalties for Jemperli (with GSK) and imsidolimab (with Vanda).
The company says it will operate a virtual model with limited FTEs, minimal operating expenses, approximately $140–$145 million in net cash at launch, and a projected >95% EBIT margin, aiming to protect and return royalty value to shareholders.
Anaptys (Nasdaq: ANAB) announced the approved spin-off of First Tracks Biotherapeutics (TRAX), expected to begin regular trading on April 20, 2026. Anaptys stockholders will receive one share of TRAX per one share of ANAB (record date April 6, 2026). First Tracks launches with $180 million in cash (including an $80 million private placement) and an initial two-year cash runway to advance three lead clinical programs.
First Tracks Biotherapeutics (Nasdaq: ANAB) secured commitments of $145 million in a private placement, including $80 million in gross proceeds to the company from sale of 5,791,478 primary shares at $13.81 per share. First Tracks Bio is expected to spin off on April 20, 2026 and to launch with $180 million in cash, providing an estimated two-year cash runway. Proceeds will fund general corporate purposes, including clinical development of ANB033. The financing involves institutional investors and placement agents Leerink, Barclays and UBS.
Anaptys (NASDAQ: ANAB) announced a $100 million stock repurchase plan and a business update ahead of the planned spin-off of First Tracks Biotherapeutics (TRAX) targeted for April 20, 2026. Post-spin-off, Anaptys will manage royalty and financial collaborations for Jemperli and imsidolimab, operate with ~10 FTEsannualized expenses <$10M and initial net cash and investments of approximately $140–$145M.
The company appointed Susannah Gray to the board, engaged Piper Sandler as exclusive financial advisor, and anticipates paying down remaining non-recourse debt to Sagard by end of Q2 2027.
Anaptys (Nasdaq: ANAB) announced a planned Q2 2026 spin-off of its biopharma portfolio into a new public company, First Tracks Biotherapeutics (TRAX), while retaining a royalty-management company under the Anaptys name.
Key financials: year-end cash and investments of $311.6M, Q4 2025 net income of $49.6M, and full-year 2025 net loss of $13.2M. Jemperli sales reached $343M in Q4 2025, implying a ~$1.4B annualized run rate and potential >$390M annualized royalties to Anaptys at GSK peak guidance.
Vanda Pharmaceuticals (Nasdaq: VNDA) announced FDA acceptance of its Biologics License Application for imsidolimab to treat Generalized Pustular Psoriasis (GPP), with a target action date of December 12, 2026.
Pivotal GEMINI-1/2 studies showed 53% achieving GPPPGA 0/1 at Week 4 versus 13% placebo; efficacy maintained during ~2-year monthly maintenance, with a favorable safety profile and low anti-drug antibodies.